Stock comparison

LLYvsRPRX

Eli Lilly and CovsRoyalty Pharma PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

LLY

Eli Lilly and Co

$917.65

-12.96%

Pharmaceuticals$884.0BNYSE

RPRX

Royalty Pharma PLC

$49.64

+29.34%

Pharmaceuticals$27.1BNASDAQ

60-day price, rebased to 100

LLY -11.52% · RPRX +19.10%

Round-by-round

LLY 3·RPRX 3

EdgeRPRX

Valuation upside

-70.70% vs -57.50% to DCF fair value

EdgeLLY

Balance-sheet strength

Altman Z 8.14 vs 2.25

EdgeLLY

Fundamental quality

Piotroski 8.00 vs 5.00 (of 9)

EdgeRPRX

Growth + margins

Rule-of-40 53.90 vs 109.80

EdgeRPRX

60-day momentum

-11.52% vs +19.10% price return

EdgeLLY

Market-cap liquidity

$884.0B vs $27.1B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onLLYorRPRX

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.